Law firm Eversheds has advised Recordati Spa, a major Italian group of pharmaceutical laboratories, on the acquisition of 67% of shares in Tunisian pharmaceutical company Opalia Pharma.

Milan-based Recordati is a specialty pharmaceutical group with a global reach. Opalia Pharma S.A. is a Tunisian pharmaceutical company that markets branded generic drugs with leading products in dermatology and in the gastrointestinal and respiratory therapeutic areas.

Recordati was advised Eversheds Paris in collaboration with Eversheds El Heni in Tunisia, with partners Boris Martor, Farès Koussay El Heni, Raouf Mohamed El Heni and Dan Roskis, working closely with associates Jawad Fassi-Fehri and Imène Boukadoum. Further counsel was provided by Anna Buscall of Arnold & Porter.

Boris said:

“This is a highly strategic deal for Recordati as it continues to strengthen its international footprint. The Tunisian pharmaceutical market is ripe for growth and international investment, like this from Recordati, can help to drive the market forward, on to a global playing field. This deal is a strong start to our newly announced collaboration with El Heni, and a further demonstration of our capabilities in Africa.”